Current status of growth hormone therapy in Prader–Willi syndrome

References

• Burman P, Ritzen EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr. Rev. 22, 787–799 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, tauberM. Recommendations for the diagnosis and management of Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 93(11), 4183–4197 (2008).
   PubMed Web of Science ®Google Scholar
• Prader A, Labhart A, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptorchidismus und oligophrenie nach myotonieartigem zustand in neugeborenalter. Schweiz. Med. Wochenschr. 86, 1260 (1956).
   Google Scholar
• Holm VA, Cassidy SB, Butler MG et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91, 398–402 (1993).
   PubMed Web of Science ®Google Scholar
• Cassidy SB, Schawartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet. Med. 14 (1), 10–26 (2012).
   PubMed Web of Science ®Google Scholar
• Gunay-Aygun M, Schwartz S, Heeger S, O’Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 108, E92 (2001).
   PubMed Web of Science ®Google Scholar
• Festen DA, de Weerd AW, van den Bossche RA, Joosten K, Hoeve H, Hokken-Koelega AC. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. J. Clin. Endocrinol. Metab. 91, 4911–4915 (2006).
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Hirsch HJ, Benarroch F, Rubinstein O, Gross-Tsur V. Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. Eur. J. Endocrinol. 162, 377–384 (2010).
   PubMed Web of Science ®Google Scholar
• Hirsch HJ, Eldar-Geva T, Benarroch F, Rubinstein O, Gross-Tsur V. Primary testicular dysfunction is a major contributor to abnormal pubertal development in males with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 94, 2262–2268 (2009).
   PubMed Web of Science ®Google Scholar
• Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. Acta Paediatr. 89, 1302–1311 (2000).
   PubMed Web of Science ®Google Scholar
• Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J. Med. Genet. 38, 792–798 (2001).
   PubMed Web of Science ®Google Scholar
• Tauber M, Diene G, Molinas C, Hebert M. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am. J. Genet. A. 146, 881–887 (2008).
   PubMed Web of Science ®Google Scholar
• Carroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83, 382–395 (1998).
   PubMed Web of Science ®Google Scholar
• Craig ME, Johnson AM, Cowell CT. Recombinant growth hormone in Prader-Willi syndrome (protocol). Cochrane Libr. 4, 1–7 (2009).
   Google Scholar
• Deal CL, Tony M, Höybye C et al. Growth Hormone Research Society Workshop Summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 98(6), E1072–E1087 (2013).
   PubMed Web of Science ®Google Scholar
• Grugni G, Marzullo P, Ragusa L et al. A. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 65, 492–499 (2006).
   PubMed Web of Science ®Google Scholar
• Hoybye C, Frystyk J, Thoren M. The growth hormone-insulinlike growth factor axis in adult patients with Prader Willi syndrome. Growth Horm. IGF Res. 13, 269–274 (2003).
   PubMed Web of Science ®Google Scholar
• Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J. Pediatr. 137, 42–49 (2000).
   PubMed Web of Science ®Google Scholar
• Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J. Pediatr. 134, 215–221 (1999).
   PubMed Web of Science ®Google Scholar
• Festen DA, de Lind van Wijngaarden R, van Eekelen M et al. Randomized controlled growth hormone trial: effects on anthropometry, body composition, and body proportions in a large group of children with Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 69, 443–451 (2008).
   PubMed Web of Science ®Google Scholar
• Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J. Clin. Endocrinol. Metab. 87, 1581–1585 (2002).
   PubMed Web of Science ®Google Scholar
• Meinhardt U, Christiansen JS, Farholt S et al. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome. Horm. Metab. Res. 45 532–536 (2013).
   PubMed Web of Science ®Google Scholar
• Angulo MA, Castro-Magana M, Lamerson M et al. Final height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am. J. Med. Genet. A 143, 1456–1461 (2007).
   Google Scholar
• Festen DA, Wevers M, Lindgren AC et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 68, 919–925 (2008).
   PubMed Web of Science ®Google Scholar
• Miller JL. Approach to the child with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 97 (11), 3837–3844 (2012).
   PubMed Web of Science ®Google Scholar
• De Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-koelega AC. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 94, 1274–1280 (2009).
   PubMed Web of Science ®Google Scholar
• Carrell AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 95 (3), 1131–1136 (2010).
   PubMed Web of Science ®Google Scholar
• Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, La Franchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 88, 2206–2212 (2003).
   PubMed Web of Science ®Google Scholar
• Carrel AL, Moerchen V, Myers SE et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J. Pediatr. 145, 744–749 (2004).
   PubMed Web of Science ®Google Scholar
• Hoybye C, Hilding A, Jacobsson H, Thoren M. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J. Clin. Endocrinol. Metab. 87, 3590–3597 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstone AP, Thomas EL, Brynes AE et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 86, 4330–4338 (2001).
   PubMed Web of Science ®Google Scholar
• Sode-Carlsen R, Farholt S, Rabben KF et al. Body Composition, endocrine and metabolic profiles in adults with Prader-Willi S yndrome. Growth Horm. IGF Res. 20, 179–184 (2010).
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin. Endocrinol. (Oxf.) 77(1), 86–93 (2011).
   Web of Science ®Google Scholar
• Butler MG, Smith BK, Lee J, Gibson C et al. Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Horm. IGF Res. 23, 81–87 (2013).
   PubMed Web of Science ®Google Scholar
• Theodoro MF, Talebizadeh Z, Butler MG. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity (Silver Spring) 14, 1685–1690 (2006).
   PubMed Web of Science ®Google Scholar
• van Mil EG, Westerterp KR, Gerver WJ, Van Marken Lichtenbelt WD, Kester ADM, Saris WHM. Body composition in Prader-Willi syndrome compared with nonsyndromal obesity: Relationship to physical activity and growth hormone function. J. Pediatr. 139, 708–714 (2001).
   PubMed Web of Science ®Google Scholar
• Van Nieuwpoort IC, Sinnema M, Castelijns JA, Twisk JW, Curfs LM, Drent ML. The GH/IGF-I axis and pituitary function and size in adults with Prader-Willi syndrome. Horm. Res. Pediatr. 75 (6), 403–411 (2011).
   PubMed Web of Science ®Google Scholar
• Sode-Carlsen R, Farholt S, Rabben KF et al. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition—results from a randomised, placebocontrolled study. J. Clin. Endocrinol. Metab. 95, 4943–4950 (2010).
   PubMedGoogle Scholar
• Sode-Carlsen R, Farholt S, Rabben KF et al. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Horm. IGF Res. 21, 185–190 (2011).
   PubMed Web of Science ®Google Scholar
• Höybye C. Endocrine and metabolic aspects of adult Prader- Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm. IGF Res. 14(1), 1–15 (2004).
   PubMed Web of Science ®Google Scholar
• Gondoni LA, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. J. Endocrinol. Invest. 31, 765–772 (2008).
   PubMed Web of Science ®Google Scholar
• Marzullo P, Marcassa C, Campini R et al. Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 92, 1364–1371 (2007).
   PubMed Web of Science ®Google Scholar
• Mogul HR, Lee PD, Whitman BY et al. Southren, Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J. Clin. Endocrinol. Metab. 93, 1238–1245 (2008).
   PubMed Web of Science ®Google Scholar
• Hoybye C. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. Acta Paediatr. 96, 410–413 (2007).
   PubMed Web of Science ®Google Scholar
• Höybye C, Thorén M, Böhm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. J. Intellect. Disabil. Res. 49(Pt 4), 245–252 (2005).
   PubMedGoogle Scholar
• Bertella L, Mori I, Grugni G et al. Quality of life and psychological well-being in GH-treated adult PWS patients: a longitudinal study. J. Intellect. Disabil. Res. 51, 302–311 (2007).
   PubMed Web of Science ®Google Scholar
• Sode-Carlsen R, Farholt S, Rabben KF et al. Assessment of physical function in adults with Prader-Willi syndrome. Disabil. Rehabil. 31, 1780–1784 (2009).
   PubMed Web of Science ®Google Scholar
• Jorgensen AP, Ueland T, Sode-Carlsen R et al. Two years of growth hormne treatment in adults with Prader-Willi syndrome do not improve the low BMD. J. Clin. Endocrinol. Metab. 98(4), E753–60 (2013)
   Web of Science ®Google Scholar
• Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev. Med. Child Neurol. 44, 248–255 (2002).
   PubMed Web of Science ®Google Scholar
• Talebizadeh Z, Butler MG. Insulin resistance and obesityrelated factors in Prader-Willi syndrome: comparison with obese subjects. Clin. Genet. 67, 230–239 (2005).
   PubMed Web of Science ®Google Scholar
• De Lind van Wijngaarden RF, Otten BJ, Festen DA et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 93, 1649–1654 (2008).
   PubMed Web of Science ®Google Scholar
• Nyunt O, Cotterill AM, Archbold SM et al. Normal cortisol response om low-dose synacthen (1 microg) test in children with Prader-Willi syndrome. J. Clin. Endocrnol. Metab. 95, E464–E467 (2008).
   Web of Science ®Google Scholar
• Farholt S, Sode-Carlsen R, Christiansen JS, östergaard JR, Höybye C. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 96, E173–E180 (2011).
   Web of Science ®Google Scholar
• Grugni G, Beccaria L, Crino A et al. Central adrenal insufficiency in young adults with Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 79(3), 371–378 (2013).
   PubMed Web of Science ®Google Scholar